Читать книгу Diagnóstico y tratamiento de la infección por el virus de la inmunodeficiencia humana, Infecciones oportunistas y trastornos relacionados - Rosa Nohemí Terán Terán - Страница 24
ОглавлениеBIBLIOGRAFÍA
1.Bloom A. The natural history and clinical features of HIV infection in adults and adolescents. UptoDate. 2016;(table 3):1–24.
2.Calvo M, Martinez E. Update on metabolic issues in HIV patients. Vol. 9, Current Opinion in HIV and AIDS. 2014. p. 332–9.
3.Guaraldi Giovanni, Prakash Manyu MC and SH-J. Morbidity in Older HIV-Infected Patients : Impact of Long-Term Antiretroviral Use. AIDS Rev. 2014;89(16):75–89.
4.Currier J. Epidemiology of cardiovascular disease and risk factors in HIV-infected patients. UpToDate Inc. 2014. p. 1–18.
5.Freiberg MS, Chang C-CH, Kuller LH, Skanderson M, Lowy E, Kraemer KL, et al. HIV Infection and the Risk of Acute Myocardial Infarction. JAMA Intern Med [Internet]. 2013;173(8):614. Available from: http://archinte.jamanetwork.com/article.aspx?doi=10.1001/jamainternmed.2013.3728
6.Hemkens LG, Bucher HC. HIV infection and cardiovascular disease. Eur Heart J. 2014;35(21):1373–81.
7.Wang T, Yi R, Green LA, Chelvanambi S, Seimetz M, Clauss M. Increased cardiovascular disease risk in the HIV-positive population on ART: potential role of HIV-Nef and Tat. Cardiovasc Pathol. 2015;24(5):279–82.
8.Cahn Pet al. Metabolic profile and cardiovascular risk factors among Latin American HIV-infected patients receiving HAART. Braz J Infect Dis. 2010;14(2):158–66.
9.Friis-Møller N, Thiébaut R, Reiss P, Weber R, Monforte AD, De Wit S, El-Sadr W, Fontas E, Worm S, Kirk O, Phillips A, Sabin CA, Lundgren JD LMD study group. Predicting the risk of cardiovascular disease in HIV-infected patients : the Data collection on Adverse Effects of Anti-HIV Drugs Study. Eur J Cardiovasc Prev Rehabilrev Rehabil. 2010;5:491–501.
10.Jarrin M. Comparación de la Circunferencia del Cuello, Indice Tobillo-Brazo, Ecuación de Framingham y Ecuación del Grupo D:A:D, como predictores de enfermedad cardiovascular en pacientes portadores de VIH con TARMA que acuden a la unidad de atención integral de PVV [Internet]. Pontificia Universidad Católica del Ecuador; 2015. Available from: http://repositorio.puce.edu.ec/handle/22000/8583
11.European Aids Clinical Society. GUÍA CLÍNICA Versión 9.0 Octubre de 2017. 2017. p. 104.
12.L Ryom, JD Lundgren, W El-Sadret al. O behalf of the D study G. Association between Cardiovascular Disease & Contemporarily Used Protease Inhibitors. In: INFLAMMATION AND AGE-RELATED COMPLICATIONS. Seatle: Abstract Number: 128LB; 2017.
13.Gilbert JM, Fitch KV, Grinspoon SK. HIV-related cardiovascular disease, statins, and the REPRIEVE trial. Top Antivir Med. 2015;23(4):146–9.
14.Feinstein MJ, Achenbach CJ, Stone NJ L-JD. RS Usefulness of Statin Therapy in HIV-Infected Patients - American Journal of Cardiology. 2015. p. 1760–6.
15.Stein JH. Management of lipid levels and cardiovascular disease in HIV-infected individuals: Just give them a statin? Top Antivir Med [Internet]. 2015;23(5):169–73. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L609720072
16.Stein JH. Management of lipid levels and cardiovascular disease in HIV-infected individuals: Just give them a statin? Top Antivir Med. 2015;23(5):169–73.
17.Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(24):e285–350.
18.Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2019;111–88.
19.Maggi P, Di Biagio A, Rusconi S, Cicalini S, D’Abbraccio M, d’Ettorre G, et al. Cardiovascular risk and dyslipidemia among persons living with HIV: A review. BMC Infect Dis. 2017;17(1):1–17.
20.Amador-Licona N, Díaz-Murillo TA, Gabriel-Ortiz G, Pacheco-Moises FP, Pereyra-Nobara TA, Guízar-Mendoza JM, et al. Omega 3 Fatty Acids Supplementation and Oxidative Stress in HIV-Seropositive Patients. A Clinical Trial. PLoS One. 2016;11(3):e0151637.
